Loading...
XSTO
VIVE
Market cap12mUSD
Jun 05, Last price  
0.23SEK
1D
-0.64%
1Q
-7.20%
Jan 2017
-95.97%
IPO
-98.50%
Name

Vivesto AB

Chart & Performance

D1W1MN
XSTO:VIVE chart
No data to show
P/E
P/S
190.37
EPS
Div Yield, %
Shrs. gr., 5y
12.88%
Rev. gr., 5y
27.27%
Revenues
656k
+553.74%
11853,22222,387,00071,158,00079,357,00030,741,000106,000891,000060,0002,070,0006,373,000172,0003,169,0001,980,000201,843,000201,843,00026,192,000100,297655,686
Net income
-12m
L-65.60%
2,505,381-7,306,969-9,757,000-5,067,000-7,105,000-17,054,000-65,960,000-65,670,000-72,381,000-105,112,000-117,497,000-141,539,000-160,243,000-118,007,000-171,020,000-10,533,000-10,533,000-138,945,000-35,249,284-12,127,042
CFO
-6m
L-18.61%
6,529,528-11,270,940-22,735,0009,00014,276,000-11,235,000-57,598,000-52,439,000-69,539,000-86,899,000-107,665,000-128,126,000-133,011,000-123,634,000-118,839,000-6,866,000-204,862,500-145,565,000-7,956,309-6,475,354
Earnings
Aug 20, 2025

Profile

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
IPO date
Jan 01, 2005
Employees
19
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑102020‑042019‑042018‑042017‑042016‑04
Income
Revenues
656
553.74%
100
-99.62%
Cost of revenue
1,061
37,301
Unusual Expense (Income)
NOPBT
(406)
(37,201)
NOPBT Margin
Operating Taxes
(3)
Tax Rate
NOPAT
(406)
(37,201)
Net income
(12,127)
-65.60%
(35,249)
-74.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,267
BB yield
-18.59%
Debt
Debt current
287
Long-term debt
5,678
Deferred revenue
Other long-term liabilities
(4,684)
Net debt
(7,674)
(7,742)
Cash flow
Cash from operating activities
(6,475)
(7,956)
CAPEX
(62)
(27)
Cash from investing activities
6,003
(4,474)
Cash from financing activities
12,724
FCF
839
(16,278)
Balance
Cash
7,645
13,678
Long term investments
30
29
Excess cash
7,642
13,701
Stockholders' equity
(181,808)
(163,530)
Invested Capital
200,657
194,698
ROIC
ROCE
EV
Common stock shares outstanding
179,348
164,402
Price
0.41
-6.11%
0.43
-83.45%
Market cap
73,084
2.43%
71,351
-93.93%
EV
65,410
63,609
EBITDA
4,999
(11,889)
EV/EBITDA
13.08
Interest
49
Interest/NOPBT